Feature | August 20, 2012

Baylor Heart Hospital First in the World to Merge Two High-Tech Systems for AFib Therapy

Merging to result in reduced procedure time and higher likelihood of favorable outcome

August 20, 2012 — The Baylor Heart Hospital in Plano, Texas, recently became the first hospital in the world to merge two highly advanced technologies for atrial fibrillation (AF) therapy.

The procedure combined the use of multi-electrode mapping (MEM) software with the Epoch platform, making the full-service cardiovascular hospital the first in the world to do so. Introduced by Biosense Webster, the software allows the physician maneuvering a MEM-enabled catheter to acquire multiple mapping points simultaneously with a higher level of detail. The Epoch platform is an advanced computer-controlled technology that allows physicians to navigate within the patient's heart with robotic precision.

Merging these two technologies means higher levels of efficiencies in mapping and correcting the patient’s cardiac arrhythmias. J. Brian DeVille, M.D., FACC, FHRS, medical director of electrophysiology and an electrophysiologist on the medical staff of the Baylor Heart Hospital, said this first-in-the-world procedure is an important step to further advancing patient care in the arena of cardiac electrophysiology.

“The integration of these two technologies confirms the Heart Hospital Baylor Plano’s commitment to excellence in patient care and providing advanced treatment to our patients,” DeVille said. “Our goal is always to seek ways to further minimize risk to the patient, which then increases the probability of favorable outcomes.”

Mark Valentine, the hospital’s president, added, “The Heart Hospital is fully committed to improving patient outcomes and that involves implementing advanced technologies that will help us fulfill that goal. We consistently strive to be on the forefront when it comes to innovation because we know that ultimately that is what will serve our patients’ interests in positive ways and help us continue to provide safe, quality, compassionate care.”

For more information: www.thehearthospitalbaylor.com

Related Content

TCT 2016, TCT.16, main arena, late breaking trials, transcatheter cardiovascular therapeutics

There were several hot topics that came out of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting Oct. 29 - Nov. 2, which made this month's top 20 list, including several videos. Number 4 on the list of content was the result of the EXCEL Trial key TCT late-breaker, which showed stenting is equal in outcomes to surgery for the first time, when using one of the latest generation drug-eluting stents. 

Feature | December 05, 2016
December 5, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional
Boston Scientific, HeartLogic Heart Failure Diagnostic Service, MultiSENSE trial data, AHA Scientific Sessions 2016
News | Heart Failure| November 18, 2016
Boston Scientific recently announced results from the first clinical trial evaluating the performance of the HeartLogic...
atrial fibrillation, warfarin, dementia, Intermountain Medical Center Heart Institute, American Heart Association, AHA Scientific Sessions 2016
News | Atrial Fibrillation| November 15, 2016
Atrial fibrillation patients who use warfarin to lower risk of stroke are at higher risk of developing dementia than...
Medtronic, Claria MRI Quad CRT-D SureScan, FDA approval
Technology | Cardiac Resynchronization Therapy Devices (CRT)| November 15, 2016
Medtronic plc  has received U.S. Food and Drug Administration (FDA) approval for the Claria MRI Quad Cardiac...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Sponsored Content | Videos | Heart Valve Technology| November 14, 2016
William Abraham, M.D., FACC, discusses advances in heart failure device treatment technologies at the Transcatheter C
Siemens, FDA clearance, Xprecia Stride Coagulation Analyzer, point-of-care testing
Technology | Point of Care Testing| November 10, 2016
Siemens Healthineers announced U.S. Food and Drug Administration (FDA) 510(k) clearance for a hand-held portable...
genetic testing, sudden cardiac death of teen, Mayo Clinic Proceedings
News | Genetic Testing| November 09, 2016
The recent, sudden death of a 13-year-old boy resulted in more than 20 relatives being incorrectly diagnosed as having...
transcatheter aortic valve replacement, pacemakers, implantation, post-TAVR implantation, worse outcomes, study
News | EP Lab| November 09, 2016
Patients who undergo minimally invasive heart valve replacement, known as transcatheter aortic valve replacement (TAVR...
Overlay Init